Similar articles for PMID: 34446452

Year	Number of Results
2005	1
2012	1
2013	2
2014	2
2015	5
2016	13
2017	14
2018	15
2019	19
2020	16
2021	11
2022	4
2023	3
2024	8

1

To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.

Srinivas S, Iagaru A. Srinivas S, et al. J Nucl Med. 2021 Nov;62(11):1487-1488. doi: 10.2967/jnumed.121.263035. Epub 2021 Aug 26. J Nucl Med. 2021. PMID: 34446452 Free PMC article. No abstract available.

2

PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.

Wester HJ, Schottelius M. Wester HJ, et al. Semin Nucl Med. 2019 Jul;49(4):302-312. doi: 10.1053/j.semnuclmed.2019.02.008. Epub 2019 Apr 30. Semin Nucl Med. 2019. PMID: 31227053 Review.

3

Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.

Naik M, Khan SR, Lewington V, Challapalli A, Eccles A, Barwick TD. Naik M, et al. Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092. Br J Radiol. 2024. PMID: 38733571 Free PMC article. Review.

4

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, Kopka K, Haberkorn U. Kratochwil C, et al. Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8. doi: 10.1007/s00259-014-2978-1. Epub 2015 Jan 9. Eur J Nucl Med Mol Imaging. 2015. PMID: 25573634 No abstract available.

5

A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Verburg FA, Luster M. Verburg FA, et al. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1611-1613. doi: 10.1007/s00259-017-3767-4. Epub 2017 Jul 4. Eur J Nucl Med Mol Imaging. 2017. PMID: 28677048 No abstract available.

6

Development of ¹⁸F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior.

Potemkin R, Strauch B, Kuwert T, Prante O, Maschauer S. Potemkin R, et al. Mol Pharm. 2020 Mar 2;17(3):933-943. doi: 10.1021/acs.molpharmaceut.9b01179. Epub 2020 Feb 17. Mol Pharm. 2020. PMID: 32011889

7

[PSMA-targeted radioligand therapy in prostate cancer].

Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M. Heck MM, et al. Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Urologe A. 2017. PMID: 27885457 Review. German.

8

[PSMA-based theranostics for prostate cancer : From imaging to treatment].

Ilhan H, la Fougère C, Krause BJ. Ilhan H, et al. Urologe A. 2020 May;59(5):617-625. doi: 10.1007/s00120-020-01193-x. Urologe A. 2020. PMID: 32377764 German.

9

Prostate-specific membrane antigen radioligand therapy of prostate cancer.

Beheshti M, Heinzel A, von Mallek D, Filss C, Mottaghy FM. Beheshti M, et al. Q J Nucl Med Mol Imaging. 2019 Mar;63(1):29-36. doi: 10.23736/S1824-4785.19.03155-8. Epub 2019 Jan 15. Q J Nucl Med Mol Imaging. 2019. PMID: 30644306 Review.

10

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Hölscher T, Wust P, Ganswindt U, Baur ADJ, Zöphel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C. Zschaeck S, et al. Radiat Oncol. 2018 May 11;13(1):90. doi: 10.1186/s13014-018-1047-5. Radiat Oncol. 2018. PMID: 29751842 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year